Trial · NCT04589130
Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.
NCT04589130, Phase 4, Unknown, St. Joseph's Healthcare Hamilton
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program. Trials, record NCT04589130. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04589130
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.
- NCT number
- NCT04589130
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 89 participants, actual
- Lead sponsor
- St. Joseph's Healthcare Hamilton
- Conditions
- Obesity
- Interventions
- Contrave 8Mg-90Mg Extended-Release Tablet, Placebo
- First posted
- 2020-10-19
- Last updated
- 2023-08-03
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Percentage Change in Body Weight | Week 0 to Week 28 | To determine the weight loss maintenance and any further weight loss effect of Contrave with usual care compared to placebo with usual care, in a post behaviour modification program population. |
| Primary | Percentage of participants who maintained their weight | Week 0 to Week 28 | To determine the weight loss maintenance effect of Contrave with usual care compared to placebo with usual care, in post behaviour modification program population (Participants who had a weight regain less than or equal to 3% of weight from Week 0 - 28 will be regarded as maintainers). |
| Primary | Percentage of participants who lost more than of equal to 5% of body weight | Week 0 to Week 28 | To determine any further weight loss effect of Contrave with usual care compared to placebo with usual care, in a post behaviour modification program population. |
| Secondary | Mean Percentage Change in Body Weight from baseline to week 52 | Week 0 to Week 52 | To determine the weight loss maintenance and any further weight loss effect of Contrave compared to placebo, in a post behaviour modification program population. |
| Secondary | Percentage of participants who maintained their weight | Week 0 to Week 52 | To determine the weight loss maintenance effect of Contrave compared to placebo, in a post behaviour modification program population (Participants who had a weight regain less than or equal to 3% of weight from Week 0 - 52 will be regarded as maintainers). |
| Secondary | Percentage of participants who lost more than or equal to 5% of body weight | Week 0 to Week 52 | To determine any further weight loss effect of Contrave compared to placebo, in a post behaviour modification program population. |
| Secondary | Percentage of participants who lost more than or equal to 10% of body weight | Week 0 to Week 28 and Week 52 | To determine any further weight loss effect of Contrave compared to placebo, in a post behaviour modification program population. |
| Secondary | Percentage of participants with weight regain (≥ 5% from baseline) | Week 0 to Week 28 and Week 52 | To determine any weight regain in participants taking Contrave compared to placebo, in a post behaviour modification program population. |
| Secondary | Percentage of subjects with weight regain (≥ 10% from baseline) | Week 0 to Week 28 and Week 52 | To determine any weight regain in participants taking Contrave compared to placebo, in a post behaviour modification program population. |
| Secondary | Mean Percentage Change in Body Weight in participants who crossed over from placebo to Contrave | Week 28 to Week 52 | To determine any weight loss or maintenance effect of Contrave following placebo control phase. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04589130
GET https://conductscience.org/api/trials/v1/NCT04589130/registered?page=2